FINAL STUDY GUIDE NUR 607 Questions with
Detailed Verified Answers
Pharmacokinetics
Ans: effect of the body on a drug.
Pharmacodynamics
Ans: effect of a drug on the body.
Live Vaccines
Ans: measles, mumps, and rubella (MMR), varicella, rotavirus, smallpox, yellow fever,
oral polio, FluMist, cholera. Should not be given to pts who are immunocompromised,
have a febrile illness or are pregnant.
Vaccines for Adults > 65
Ans: COVID-19, influenza, pneumococcal, shingles (zoster), and Tdap or Td.
Vaccines for Pts with Chronic Health Conditions
Ans: COVID-19, influenza, pneumococcal, hepatitis B, Tdap or Td, shingles.
Vaccines for COPD Pts
Ans: influenza, two pneumococcal vaccines
Deferring
© Get it right 2025 Getaway - Stuvia US All rights reserved
,Click here for more: Scholars nexus
Ans: it is okay to administer vaccines to pts with mild illness; however, they should be
deferred for pts with mild to moderate illness (running a fever, taking abx, etc.).
• Tdap CONTRAINDICATIONS
Ans: pts with progressive neurologic disorders.
• MMR contraindications
Ans: pregnant or immunocompromised pts, pts with a hx of anaphylactic reaction to
eggs, allergy to neomycin or gelatin.
• Varicella contraindications
Ans: allergy to neomycin, pts taking high-dose steroids, pregnant or
immunocompromised pts.
First Line Treatment DM
Ans: a biguanide, such as Metformin.
Biguanides
Ans: increases insulin sensitivity, decreases hepatic glucose, decreases intestinal
glucose absorption. 1.5 - 2% decrease in A1C. Low hypoglycemic risk. Weight neutral.
Sodium-Glucose Co-Transporter 2 (SGLT2)
© Get it right 2025 Getaway - Stuvia US All rights reserved
, Click here for more: Scholars nexus
Ans: decreases renal glucose absorption, increases urinary glucose excretion. 0.5 - 1%
A1C reduction. Low risk of hypoglycemia. Can help pts lose weight. Excretes glucose
into the urine, so these put pts at higher risk for yeast infections. Examples: Invokana,
Farxiga, Jardiance (empagliflozin).
Dipeptidyl Peptidase-4 Inhibitors (DDP-4)
Ans: increases insulin secretion, decreases glucagon secretion. Reduces A1C by 0.5 -
1%. Low risk of hypoglycemia. Weight neutral. Examples: Tradjenta, Onglyza, Januvia
(sitagliptin)
Sulfonylureas
Ans: increases insulin release from pancreatic B cells. Reduces A1C by 1 - 1.5%. High
risk of hypoglycemia. Can cause weight gain. When dosing, start low and titrate to
reduce risk of hypoglycemia. Examples: glimepiride (Amaryl), glipizide (Glucotrol)
Thiazolidinediones (TZD)
Ans: increases insulin sensitivity in muscle and fat. Reduces A1C by 1 - 1.5%. Low risk
of hypoglycemia. Can cause weight gain. Examples: pioglitazone (Actos).
Glucose-Like Peptide (GLP-1) Receptor Agonist
Ans: decreases A1C by 1 - 2.1%. Low risk of hypoglycemia. Causes weight loss.
Dulaglutide (Trulicity), liraglutide (Victoza) and semaglutide (Ozempic) have
cardiovascular benefit.
Glucose Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonist
© Get it right 2025 Getaway - Stuvia US All rights reserved